Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 10, 2014, Pages 2082-2091

  Pallotta, Maria Teresa ^a   Orabona, Ciriana ^a   Bianchi, Roberta ^a   Vacca, Carmine ^a   Fallarino, Francesca ^a   Belladonna, Maria Laura ^a   Volpi, Claudia ^a   Mondanelli, Giada ^a   Gargaro, Marco ^a   Allegrucci, Massimo ^a   Talesa, Vincenzo Nicola ^a   Puccetti, Paolo ^a   Grohmann, Ursula ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Autoimmune diabetes; IDO1; Immune regulation; Non canonical NF B; Non obese diabetic (NOD) mice; Plasmacytoid dendritic cells; Tryptophan catabolism

Indexed keywords

MUS;

IDO1 PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MESSENGER RNA;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELLULAR IMMUNITY; CYTOLOGY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, NUDE; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN; T-LYMPHOCYTES, REGULATORY;

EID: 84908052248     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12360     Document Type: Article

References (54)

1. Kishimoto H, Sprent J. A defect in central tolerance in NOD mice. Nat Immunol. 2001; 2: 1025-31.
2. Colucci F, Bergman ML, Penha-Goncalves C, et al. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA. 1997; 94: 8670-4.
3. Liu J, Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-κB expression and binding to the IL-12 p40 promoter. Immunol. 2002; 169: 581-6.
4. Suarez-Pinzon WL, Mabley JG, Strynadka K, et al. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. J Autoimmun. 2001; 16: 449-55.
5. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol. 1993; 150: 2534-43.
6. Fallarino F, Bianchi R, Orabona C, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med. 2004; 200: 1051-62.
7. Alyanakian MA, Grela F, Aumeunier A, et al. Transforming growth factor-β and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes. 2006; 55: 179-85.
8. Bach JF. Infections and autoimmune diseases. J Autoimmun. 2005; 25(Suppl.): 74-80.
9. Fallarino F, Volpi C, Zelante T, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol. 2005; 183: 6303-12.
10. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004; 5: 1219-26.
11. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010; 234: 142-62.
12. + regulatory T cells. J Immunol. 2004; 173: 4433-42.
13. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity. 2008; 29: 352-61.
14. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008; 8: 594-606.
15. Nikolic T, Welzen-Coppens JM, Leenen PJ, et al. Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy. Immunobiology. 2009; 214: 791-9.
16. Allen JS, Pang K, Skowera A, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009; 58: 138-45.
17. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat Rev Immunol. 2007; 7: 817-23.
18. Huang L, Baban B, Johnson BA 3rd, et al. Dendritic cells, indoleamine 2, 3 dioxygenase and acquired immune privilege. Int Rev Immunol. 2010; 29: 133-55.
19. Grohmann U, Fallarino F, Bianchi R, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med. 2003; 198: 153-60.
20. Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011; 12: 870-8.
21. Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2, 3-dioxygenase. Mol Med. 2012; 18: 834-42.
22. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002; 3: 1097-101.
23. Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol. 2004; 5: 1134-42.
24. Orabona C, Pallotta MT, Volpi C, et al. SOCS3 drives proteasomal degradation of indoleamine 2, 3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA. 2008; 105: 20828-33.
25. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med. 2007; 13: 579-86.
26. Belladonna ML, Volpi C, Bianchi R, et al. Cutting edge: autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol. 2008; 181: 5194-8.
27. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008; 451: 211-5.
28. Volpi C, Fallarino F, Pallotta MT, et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun. 2013; 4: 1852.
29. Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11: 312-9.
30. Grohmann U, Bianchi R, Orabona C, et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol. 2003; 171: 2581-7.
31. + T cell reactivity. Eur J Immunol. 1994; 24: 1446-52.
32. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology. 2009; 127: 299-311.
33. Quintana FJ. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology. 2013; 138: 183-9.
34. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478: 197-203.
35. Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010; 185: 3190-8.
36. Ng D, Gommerman JL. The regulation of immune responses by DC derived type I IFN. Front Immunol. 2013; 4: 94.
37. Li Q, Xu B, Michie SA, et al. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008; 105: 12439-44.
38. Belladonna ML, Orabona C, Grohmann U, et al. TGF-β and kynurenines as the key to infectious tolerance. Trends Mol Med. 2009; 15: 41-9.
39. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004; 25: 280-8.
40. Taylor MW, Feng GS. Relationship between interferon-γ, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 1991; 5: 2516-22.
41. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281: 1191-3.
42. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004; 4: 762-74.
43. Platten M, Ho PP, Youssef S, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005; 310: 850-5.
44. Lan Z, Ge W, Arp J, et al. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2, 3-dioxygenase. Transplantation. 2010; 90: 1286-93.
45. + T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci. 2011; 52: 2640-8.
46. Rubtsov YP, Rudensky AY. TGFβ signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol. 2007; 7: 443-53.
47. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 1997; 7: 727-38.
48. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med. 1999; 5: 601-4.
49. Rosmalen JG, van Ewijk W, Leenen PJ. T-cell education in autoimmune diabetes: teachers and students. Trends Immunol. 2002; 23: 40-6.
50. Weaver DJ Jr, Poligone B, Bui T, et al. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive IκB kinase. J Immunol. 2001; 167: 1461-8.
51. Wheat W, Kupfer R, Gutches DG, et al. Increased NF-κB activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur J Immunol. 2004; 34: 1395-404.
52. Saxena V, Ondr JK, Magnusen AF, et al. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol. 2007; 179: 5041-53.
53. Alexander AM, Crawford M, Bertera S, et al. Indoleamine 2, 3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes. 2002; 51: 356-65.
54. Sobel DO, Han J, Williams J, et al. Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse. J Autoimmun. 2002; 19: 129-37.